{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T18:03:51Z","timestamp":1789495431272,"version":"build-2803163510"},"reference-count":29,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}],"id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Additional treatment options are needed for patients with hospital-acquired and ventilator-associated bacterial pneumonia (HABP\/VABP) caused by carbapenem-resistant pathogens. This subgroup analysis examined clinical and microbiologic outcomes in participants from RESTORE-IMI 2 treated with imipenem\/cilastatin\/relebactam (IMI\/REL), stratified by baseline lower respiratory tract (LRT) isolate susceptibility to imipenem. Emergence of nonsusceptibility to IMI\/REL during treatment was also evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Baseline LRT specimens were obtained \u226448 hours before screening, identified at a central laboratory, and susceptibility determined per the Clinical and Laboratory Standards Institute breakpoints. Outcomes for participants who received IMI\/REL, with \u22651 imipenem-nonsusceptible, imipenem\/REL-susceptible baseline LRT pathogen were compared with participants with imipenem-susceptible pathogens. Emergence of nonsusceptibility to imipenem\/REL was also assessed, and isolates were characterized molecularly.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In total, 215 participants in the microbiologic-modified intent-to-treat population received IMI\/REL, of whom 112 were infected with imipenem-susceptible pathogens and 18 with imipenem-nonsusceptible, imipenem\/REL-susceptible pathogens and were included in this analysis. Of these 18 participants, 88.9% were in the intensive care unit and 83.3% had one gram-negative baseline pathogen. Day 28 all-cause mortality was 22.2% and 18.8% (adjusted difference: 7.3 [\u22128.8 to 31.1]) for participants who received IMI\/REL for the treatment of HABP\/VABP caused by imipenem-nonsusceptible versus imipenem-susceptible pathogens, respectively. Of a total of 192 isolates, 59 gram-negative isolates (baseline isolates that were nonsusceptible to imipenem and subsequent isolates of the same species from the same participants) were characterized using multiplex polymerase chain reaction and sequencing techniques. Emergence of nonsusceptibility to imipenem\/REL occurred in isolates from three of the 112 participants with indicated imipenem-susceptible baseline pathogens (two isolates of\n                      <jats:italic>Pseudomonas aeruginosa<\/jats:italic>\n                      and one isolate of\n                      <jats:italic>Klebsiella pneumoniae<\/jats:italic>\n                      ).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Day 28 all-cause mortality was similar among participants treated with IMI\/REL, regardless of baseline pathogen susceptibility to imipenem. Emergence of nonsusceptibility to imipenem\/REL on treatment was low.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec005\">\n                    <jats:title>Clinical trials registration<\/jats:title>\n                    <jats:p>\n                      ClinicalTrials.gov (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02493764\" xlink:type=\"simple\">NCT02493764<\/jats:ext-link>\n                      ).\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0357288","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T17:22:32Z","timestamp":1789492952000},"page":"e0357288","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Imipenem\/cilastatin\/relebactam treatment of hospital-acquired\/ventilator-associated bacterial pneumonia caused by imipenem-nonsusceptible pathogens: Subgroup analysis and molecular characterization of isolates from the RESTORE-IMI 2 clinical study"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1490-5455","authenticated-orcid":true,"given":"Katherine","family":"Young","sequence":"first","affiliation":[{"name":"Merck & Co., Inc","place":["Rahway, New Jersey, United States of America"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Andrew","family":"DeRyke","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc","place":["Rahway, New Jersey, United States of America"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W.","family":"Hilbert","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc","place":["Rahway, New Jersey, United States of America"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria C.","family":"Losada","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc","place":["Rahway, New Jersey, United States of America"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiejun","family":"Du","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc","place":["Rahway, New Jersey, United States of America"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Paschke","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc","place":["Rahway, New Jersey, United States of America"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke F.","family":"Chen","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc","place":["Rahway, New Jersey, United States of America"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,9,15]]},"reference":[{"key":"pone.0357288.ref001","unstructured":"Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2019. Atlanta, GA: U.S. Department of Health and Human Services, CDC. 2019."},{"issue":"3","key":"pone.0357288.ref002","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance","volume":"18","author":"A-P Magiorakos","year":"2012","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"pone.0357288.ref003","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1186\/s12866-021-02293-0","article-title":"Increased gene expression and copy number of mutated blaKPC lead to high-level ceftazidime\/avibactam resistance in Klebsiella pneumoniae","volume":"21","author":"L Sun","year":"2021","journal-title":"BMC Microbiol"},{"issue":"9","key":"pone.0357288.ref004","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.1128\/AAC.48.9.3573-3575.2004","article-title":"Lack of association between hypermutation and antibiotic resistance development in Pseudomonas aeruginosa isolates from intensive care unit patients","volume":"48","author":"O Guti\u00e9rrez","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"pone.0357288.ref005","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01432-20","article-title":"In Vitro Activity of WCK 5222 (Cefepime-Zidebactam) against Worldwide Collected Gram-Negative Bacilli Not Susceptible to Carbapenems","volume":"64","author":"JA Karlowsky","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"pone.0357288.ref006","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.3390\/antibiotics11081108","article-title":"Characterization of Carbapenem-Resistant K. Pneumoniae Isolated from Intensive Care Units of Zagazig University Hospitals","volume":"11","author":"NHM Gandor","year":"2022","journal-title":"Antibiotics"},{"issue":"7","key":"pone.0357288.ref007","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.3201\/eid2007.121004","article-title":"Deaths attributable to carbapenem-resistant Enterobacteriaceae infections","volume":"20","author":"ME Falagas","year":"2014","journal-title":"Emerg Infect Dis"},{"issue":"1","key":"pone.0357288.ref008","first-page":"15","article-title":"Carbapenem resistance: overview of the problem and future perspectives","volume":"3","author":"G Meletis","year":"2016","journal-title":"Ther Adv Infect Dis"},{"key":"pone.0357288.ref009","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.cll.2017.01.005","article-title":"Carbapenem-Resistant Enterobacteriaceae","volume":"37","author":"A Iovleva","year":"2017","journal-title":"Clin Lab Med"},{"issue":"2","key":"pone.0357288.ref010","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1093\/cid\/ciac268","article-title":"Infectious Diseases Society of America 2022 Guidance on the Treatment of Extended-Spectrum \u03b2-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa)","volume":"75","author":"PD Tamma","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"4","key":"pone.0357288.ref011","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.cmi.2021.11.025","article-title":"European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine)","volume":"28","author":"M Paul","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"pone.0357288.ref012","article-title":"Treatment Options for Carbapenem-resistant Gram-negative Bacterial Infections","volume":"69","author":"Y Doi","year":"2019","journal-title":"Clin Infect Dis"},{"key":"pone.0357288.ref013","unstructured":"European Medicines Agency. Recarbrio 500 mg\/500 mg\/250 mg powder for solution for infusion: summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/recarbrio-epar-product-information_en.pdf.\u00a02020. Accessed 2025 September 19."},{"key":"pone.0357288.ref014","unstructured":"US Food and Drug Administration. RECARBRIO (imipenem\/cilastatin\/relebactam). Prescribing Information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/212819s002lbl.pdf 2022. Accessed 2025 September 19."},{"issue":"11","key":"pone.0357288.ref015","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciaa803","article-title":"A Randomized, Double-blind, Multicenter Trial Comparing Efficacy and Safety of Imipenem\/Cilastatin\/Relebactam Versus Piperacillin\/Tazobactam in Adults With Hospital-acquired or Ventilator-associated Bacterial Pneumonia (RESTORE-IMI 2 Study)","volume":"73","author":"I Titov","year":"2021","journal-title":"Clin Infect Dis"},{"key":"pone.0357288.ref016","article-title":"Performance Standards for Antimicrobial Susceptibility Testing","author":"JS Lewis","year":"2025","journal-title":"Wayne, PA: Clinical and Laboratory Standards Institute"},{"issue":"8","key":"pone.0357288.ref017","doi-asserted-by":"crossref","first-page":"4743","DOI":"10.1128\/AAC.00220-16","article-title":"In Vitro Susceptibility of Global Surveillance Isolates of Pseudomonas aeruginosa to Ceftazidime-Avibactam (INFORM 2012 to 2014)","volume":"60","author":"WW Nichols","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"pone.0357288.ref018","doi-asserted-by":"crossref","first-page":"3606","DOI":"10.1128\/AAC.05186-14","article-title":"Trends in susceptibility of Escherichia coli from intra-abdominal infections to ertapenem and comparators in the United States according to data from the SMART program, 2009 to 2013","volume":"59","author":"SH Lob","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"pone.0357288.ref019","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s12866-019-1522-7","article-title":"In vitro studies evaluating the activity of imipenem in combination with relebactam against Pseudomonas aeruginosa","volume":"19","author":"K Young","year":"2019","journal-title":"BMC Microbiol"},{"issue":"9","key":"pone.0357288.ref020","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1093\/cid\/ciz530","article-title":"RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem\/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections","volume":"70","author":"J Motsch","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"5","key":"pone.0357288.ref021","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/j.1469-0691.2012.03821.x","article-title":"Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe","volume":"18","author":"R Cant\u00f3n","year":"2012","journal-title":"Clin Microbiol Infect"},{"issue":"4","key":"pone.0357288.ref022","first-page":"507","article-title":"The Intriguing Carbapenemases of Pseudomonas aeruginosa: Current Status, Genetic Profile, and Global Epidemiology","volume":"95","author":"D Hammoudi Halat","year":"2022","journal-title":"Yale J Biol Med"},{"issue":"12","key":"pone.0357288.ref023","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1093\/cid\/ciy378","article-title":"Difficult-to-Treat Resistance in Gram-negative Bacteremia at 173 US Hospitals: Retrospective Cohort Analysis of Prevalence, Predictors, and Outcome of Resistance to All First-line Agents","volume":"67","author":"SS Kadri","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"12","key":"pone.0357288.ref024","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1093\/cid\/ciaa384","article-title":"Gram-negative Bacteria With Difficult-to-Treat Resistance: A Moving Target","volume":"72","author":"MN Al-Hasan","year":"2021","journal-title":"Clin Infect Dis"},{"key":"pone.0357288.ref025","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jgar.2024.03.020","article-title":"Global trends in carbapenem- and difficult-to-treat-resistance among World Health Organization priority bacterial pathogens: ATLAS surveillance program 2018-2022","volume":"37","author":"MG Wise","year":"2024","journal-title":"J Glob Antimicrob Resist"},{"issue":"5","key":"pone.0357288.ref026","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.02927-22","article-title":"Imipenem-Relebactam Susceptibility in Enterobacterales Isolates Recovered from ICU Patients from Spain and Portugal (SUPERIOR and STEP Studies)","volume":"10","author":"M Hern\u00e1ndez-Garc\u00eda","year":"2022","journal-title":"Microbiol Spectr"},{"issue":"12","key":"pone.0357288.ref027","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1093\/cid\/ciaa381","article-title":"In Vitro Activity of Imipenem\/Relebactam and Ceftolozane\/Tazobactam Against Clinical Isolates of Gram-negative Bacilli With Difficult-to-Treat Resistance and Multidrug-resistant Phenotypes-Study for Monitoring Antimicrobial Resistance Trends, United States 2015-2017","volume":"72","author":"JA Karlowsky","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"1","key":"pone.0357288.ref028","doi-asserted-by":"crossref","first-page":"3957","DOI":"10.1038\/s41467-019-11756-y","article-title":"OmpK36-mediated Carbapenem resistance attenuates ST258 Klebsiella pneumoniae in vivo","volume":"10","author":"JLC Wong","year":"2019","journal-title":"Nat Commun"},{"issue":"4","key":"pone.0357288.ref029","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1093\/cid\/ciac097","article-title":"Evolution of Imipenem-Relebactam Resistance Following Treatment of Multidrug-Resistant Pseudomonas aeruginosa Pneumonia","volume":"75","author":"RK Shields","year":"2022","journal-title":"Clin Infect Dis"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0357288","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T17:22:39Z","timestamp":1789492959000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0357288"}},"subtitle":[],"editor":[{"given":"Iddya","family":"Karunasagar","sequence":"first","affiliation":[{"name":"Nitte University","place":["INDIA"]}],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,9,15]]},"references-count":29,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9,15]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0357288","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,15]]}}}